Tolerability with no loss of efficacy after overnight conversion from immediate-release ropinirole to an extended-release formulation - ropinirole CR - in restless legs syndrome

被引：0
|
作者：
Isaacson, S.
Castiglia, M.
Hodge, R.
机构：
来源：
PARKINSONISM & RELATED DISORDERS | 2007年 / 13卷
关键词：
D O I：
10.1016/S1353-8020(08)70529-7
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S74 / S75
页数：2
相关论文
共 50 条
  • [31] Switching to extended-release carbamazepine capsules from immediate-release formulations: Evaluation of safety and tolerability in patients with epilepsy
    Charlet, MP
    NEUROLOGY, 2005, 64 (06) : A117 - A117
  • [32] BUDGET IMPACT OF SWITCHING FROM AN EXTENDED-RELEASE TO AN IMMEDIATE-RELEASE FORMULATION OF TACROLIMUS IN RENAL TRANSPLANT RECIPIENTS IN SPAIN
    Sanz-Granda, A.
    Ramos-Verde, A.
    Aguinaga-Barrilero, A.
    Rebollo-Laserna, F. J.
    VALUE IN HEALTH, 2016, 19 (07) : A517 - A517
  • [33] Pharmacokinetics of conversion from twice daily immediate-release to once daily extended-release lamotrigine (COMPASS Study)
    Ali, Imran
    Oliver-Willwong, Ruth
    Tompson, Debra J.
    Hammer, Anne
    Vuong, Alain
    Zhu, Li
    Messenheimer, John
    NEUROLOGY, 2007, 68 (12) : A126 - A126
  • [34] Pharmacokinetics of conversion from twice daily immediate-release to once daily extended-release lamotrigine (COMPASS study)
    Ali, I.
    Oliver-Willwong, R.
    Tompson, D. J.
    Hammer, A.
    Vuong, A.
    Zhu, L.
    Messenheimer, J.
    ANNALS OF NEUROLOGY, 2007, 62 : S139 - S140
  • [35] Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine
    Miller, AD
    Krauss, GL
    Hamzeh, FM
    ACTA NEUROLOGICA SCANDINAVICA, 2004, 109 (06): : 374 - 377
  • [36] Switch from Immediate-release Pramipexole to Extended-release Pramipexole: The Safety and Efficacy Characteristics of Sixty-eight Patients
    Kuzu, Muge
    Ozer, Inci Sule
    Herdi, Oguzhan
    Tezcan, Sabiha
    Akbostanci, Muhittin Cenk
    TURKISH JOURNAL OF NEUROLOGY, 2016, 22 (03) : 114 - 116
  • [37] Comparison of pharmacodynamic parameters resulting from administration of an paliperidone extended-release tablet formulation and an immediate-release formulation of risperidone in subjects with schizophrenia.
    Cleton, A.
    Rossenu, S.
    Talluri, K.
    Francetic, I.
    Remmenie, B.
    Janssens, L.
    Eerdekens, M.
    Boom, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S61 - S62
  • [38] Success rate, efficacy, and safety/tolerability of overnight switching from immediate-to extended-release pramipexole in advanced Parkinson's disease
    Schapira, A. H. V.
    Barone, P.
    Hauser, R. A.
    Mizuno, Y.
    Rascol, O.
    Busse, M.
    Debieuvre, C.
    Fraessdorf, M.
    Poewe, W.
    EUROPEAN JOURNAL OF NEUROLOGY, 2013, 20 (01) : 180 - 187
  • [39] Efficacy, Safety, and Tolerability of Overnight Switching from Immediate- to Once Daily Extended-Release Pramipexole in Early Parkinson's Disease
    Rascol, Olivier
    Barone, Paolo
    Hauser, Robert A.
    Mizuno, Yoshikuni
    Poewe, Werner
    Schapira, Anthony H. V.
    Salin, Laurence
    Sohr, Mandy
    Debieuvre, Catherine
    MOVEMENT DISORDERS, 2010, 25 (14) : 2326 - 2332
  • [40] Improved tolerability in adolescent patients switched to extended-release carbamazepine capsules from immediate-release formulations; A community-based trial
    Wheless, JW
    NEUROLOGY, 2005, 64 (06) : A191 - A192
12345